SAN DIEGO, Oct. 19, 2012 (GLOBE NEWSWIRE) -- IDWeek 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced that two studies of its lead drug candidate, tedizolid phosphate, are being presented at IDWeek 2012. The first evaluates hematological effects of tedizolid compared to linezolid (Zyvox®) and observes significantly fewer adverse platelet outcomes in patients receiving tedizolid. A second presentation examines the pharmacokinetic behavior of Trius' antibiotic in an adolescent population.
The two IDWeek reports add to the volume of safety and clinical information about tedizolid, which has progressed from the lab to the presentation of Phase 3 results in less than five years. Tedizolid, which was previously known as torezolid phosphate and TR-701, is initially being evaluated for the treatment of acute bacterial skin and skin structure infections (ABSSSI). It is a once daily, IV and orally administered oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
"The safety and efficacy data continue to indicate that tedizolid compares very favorably to linezolid," said Jeff Stein, President and Chief Executive Officer at Trius. "In addition to a significantly lower incidence of adverse platelet outcomes, patients who were treated with tedizolid experienced statistically fewer gastrointestinal adverse events than those treated with linezolid over the same number of days of exposure."Patient Population Receiving Tedizolid has Fewer Incidences of Thrombocytopenia The first report, "A Comparative Evaluation of Adverse Platelet Outcomes among Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid Phosphate and Linezolid," summarizes the hematological results from Trius' first Phase 3 trial, ESTABLISH-1 (TR-701-112). It shows that the incidence of platelet counts below the lower limit of normal was significantly lower in patients receiving tedizolid than those treated with linezolid. Thrombocytopenia is a well-recognized toxicity signal associated with Zyvox, so this safety profile information is of particular importance for tedizolid.